nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—ABCB1—Lisinopril—dilated cardiomyopathy	0.22	0.532	CbGbCtD
Temsirolimus—ABCB1—Spironolactone—dilated cardiomyopathy	0.193	0.468	CbGbCtD
Temsirolimus—Glucose tolerance impaired—Furosemide—dilated cardiomyopathy	0.0189	0.0488	CcSEcCtD
Temsirolimus—Skin infection—Lisinopril—dilated cardiomyopathy	0.0127	0.0326	CcSEcCtD
Temsirolimus—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00778	0.0201	CcSEcCtD
Temsirolimus—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00643	0.0166	CcSEcCtD
Temsirolimus—Gastritis—Spironolactone—dilated cardiomyopathy	0.00602	0.0155	CcSEcCtD
Temsirolimus—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00557	0.0144	CcSEcCtD
Temsirolimus—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00531	0.0137	CcSEcCtD
Temsirolimus—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00531	0.0137	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.0052	0.0134	CcSEcCtD
Temsirolimus—Renal failure—Spironolactone—dilated cardiomyopathy	0.00515	0.0133	CcSEcCtD
Temsirolimus—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00508	0.0131	CcSEcCtD
Temsirolimus—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.005	0.0129	CcSEcCtD
Temsirolimus—Bladder pain—Furosemide—dilated cardiomyopathy	0.00461	0.0119	CcSEcCtD
Temsirolimus—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00445	0.0115	CcSEcCtD
Temsirolimus—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00428	0.011	CcSEcCtD
Temsirolimus—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00426	0.011	CcSEcCtD
Temsirolimus—Viral infection—Lisinopril—dilated cardiomyopathy	0.00424	0.0109	CcSEcCtD
Temsirolimus—Swelling—Furosemide—dilated cardiomyopathy	0.0042	0.0108	CcSEcCtD
Temsirolimus—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00402	0.0104	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00392	0.0101	CcSEcCtD
Temsirolimus—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00387	0.00998	CcSEcCtD
Temsirolimus—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00383	0.00986	CcSEcCtD
Temsirolimus—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00374	0.00963	CcSEcCtD
Temsirolimus—Cystitis—Lisinopril—dilated cardiomyopathy	0.00369	0.00952	CcSEcCtD
Temsirolimus—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00367	0.00945	CcSEcCtD
Temsirolimus—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00363	0.00936	CcSEcCtD
Temsirolimus—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00347	0.00894	CcSEcCtD
Temsirolimus—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00346	0.00891	CcSEcCtD
Temsirolimus—Dehydration—Furosemide—dilated cardiomyopathy	0.00344	0.00887	CcSEcCtD
Temsirolimus—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00337	0.00868	CcSEcCtD
Temsirolimus—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00334	0.00862	CcSEcCtD
Temsirolimus—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00327	0.00844	CcSEcCtD
Temsirolimus—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00322	0.0083	CcSEcCtD
Temsirolimus—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00319	0.00823	CcSEcCtD
Temsirolimus—Eczema—Lisinopril—dilated cardiomyopathy	0.00309	0.00796	CcSEcCtD
Temsirolimus—Somnolence—Spironolactone—dilated cardiomyopathy	0.00297	0.00766	CcSEcCtD
Temsirolimus—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00296	0.00762	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00289	0.00744	CcSEcCtD
Temsirolimus—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00289	0.00744	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00283	0.00729	CcSEcCtD
Temsirolimus—Renal failure—Furosemide—dilated cardiomyopathy	0.0028	0.00723	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00275	0.0139	CbGpPWpGaD
Temsirolimus—Face oedema—Lisinopril—dilated cardiomyopathy	0.00268	0.00691	CcSEcCtD
Temsirolimus—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00264	0.00681	CcSEcCtD
Temsirolimus—FKBP1A—TGF-beta receptor signaling—RPS6KB1—dilated cardiomyopathy	0.00264	0.0133	CbGpPWpGaD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—NPPA—dilated cardiomyopathy	0.00263	0.0132	CbGpPWpGaD
Temsirolimus—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.0026	0.0067	CcSEcCtD
Temsirolimus—Dehydration—Lisinopril—dilated cardiomyopathy	0.00258	0.00666	CcSEcCtD
Temsirolimus—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00253	0.00652	CcSEcCtD
Temsirolimus—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00251	0.00647	CcSEcCtD
Temsirolimus—MTOR—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00251	0.0126	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signalling—RPS6KB1—dilated cardiomyopathy	0.00251	0.0126	CbGpPWpGaD
Temsirolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—dilated cardiomyopathy	0.00248	0.0125	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00246	0.00635	CcSEcCtD
Temsirolimus—Gastritis—Lisinopril—dilated cardiomyopathy	0.00246	0.00633	CcSEcCtD
Temsirolimus—MTOR—PKB-mediated events—RPS6KB1—dilated cardiomyopathy	0.00244	0.0123	CbGpPWpGaD
Temsirolimus—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00242	0.00624	CcSEcCtD
Temsirolimus—Influenza—Lisinopril—dilated cardiomyopathy	0.0024	0.00619	CcSEcCtD
Temsirolimus—Eye disorder—Furosemide—dilated cardiomyopathy	0.00239	0.00617	CcSEcCtD
Temsirolimus—Pruritus—Spironolactone—dilated cardiomyopathy	0.00237	0.0061	CcSEcCtD
Temsirolimus—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00236	0.0118	CbGpPWpGaD
Temsirolimus—Angiopathy—Furosemide—dilated cardiomyopathy	0.00232	0.00599	CcSEcCtD
Temsirolimus—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00231	0.00596	CcSEcCtD
Temsirolimus—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00231	0.00595	CcSEcCtD
Temsirolimus—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00229	0.0059	CcSEcCtD
Temsirolimus—Dysuria—Lisinopril—dilated cardiomyopathy	0.00224	0.00578	CcSEcCtD
Temsirolimus—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00224	0.00578	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00223	0.00575	CcSEcCtD
Temsirolimus—Malnutrition—Furosemide—dilated cardiomyopathy	0.00223	0.00574	CcSEcCtD
Temsirolimus—Erythema—Furosemide—dilated cardiomyopathy	0.00223	0.00574	CcSEcCtD
Temsirolimus—Dizziness—Spironolactone—dilated cardiomyopathy	0.00221	0.0057	CcSEcCtD
Temsirolimus—MTOR—VEGFR2 mediated vascular permeability—RAC1—dilated cardiomyopathy	0.0022	0.0111	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00219	0.011	CbGpPWpGaD
Temsirolimus—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00218	0.00562	CcSEcCtD
Temsirolimus—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00217	0.0056	CcSEcCtD
Temsirolimus—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00217	0.00558	CcSEcCtD
Temsirolimus—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00215	0.00555	CcSEcCtD
Temsirolimus—Depression—Lisinopril—dilated cardiomyopathy	0.00213	0.0055	CcSEcCtD
Temsirolimus—Vomiting—Spironolactone—dilated cardiomyopathy	0.00213	0.00548	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00212	0.00547	CcSEcCtD
Temsirolimus—Rash—Spironolactone—dilated cardiomyopathy	0.00211	0.00543	CcSEcCtD
Temsirolimus—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00211	0.00543	CcSEcCtD
Temsirolimus—Renal failure—Lisinopril—dilated cardiomyopathy	0.0021	0.00542	CcSEcCtD
Temsirolimus—Headache—Spironolactone—dilated cardiomyopathy	0.0021	0.0054	CcSEcCtD
Temsirolimus—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00208	0.00536	CcSEcCtD
Temsirolimus—Anaemia—Furosemide—dilated cardiomyopathy	0.00206	0.00531	CcSEcCtD
Temsirolimus—Haematuria—Lisinopril—dilated cardiomyopathy	0.00204	0.00526	CcSEcCtD
Temsirolimus—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00202	0.0052	CcSEcCtD
Temsirolimus—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00201	0.00517	CcSEcCtD
Temsirolimus—Leukopenia—Furosemide—dilated cardiomyopathy	0.002	0.00514	CcSEcCtD
Temsirolimus—MTOR—TOR Signaling—RPS6KB1—dilated cardiomyopathy	0.00199	0.01	CbGpPWpGaD
Temsirolimus—Nausea—Spironolactone—dilated cardiomyopathy	0.00199	0.00512	CcSEcCtD
Temsirolimus—MTOR—CD28 co-stimulation—RAC1—dilated cardiomyopathy	0.00198	0.00995	CbGpPWpGaD
Temsirolimus—MTOR—IL2 signaling events mediated by PI3K—RPS6KB1—dilated cardiomyopathy	0.00195	0.0098	CbGpPWpGaD
Temsirolimus—MTOR—Alpha 6 Beta 4 signaling pathway—RAC1—dilated cardiomyopathy	0.00193	0.00971	CbGpPWpGaD
Temsirolimus—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00193	0.00496	CcSEcCtD
Temsirolimus—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00191	0.00491	CcSEcCtD
Temsirolimus—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0019	0.00489	CcSEcCtD
Temsirolimus—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00189	0.00488	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00188	0.00486	CcSEcCtD
Temsirolimus—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00188	0.00485	CcSEcCtD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NPPA—dilated cardiomyopathy	0.00188	0.00944	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00182	0.00469	CcSEcCtD
Temsirolimus—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00182	0.00468	CcSEcCtD
Temsirolimus—MTOR—TOR Signaling—RAC1—dilated cardiomyopathy	0.0018	0.00905	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00178	0.0046	CcSEcCtD
Temsirolimus—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00178	0.00459	CcSEcCtD
Temsirolimus—Skin disorder—Furosemide—dilated cardiomyopathy	0.00177	0.00455	CcSEcCtD
Temsirolimus—MTOR—IL2 signaling events mediated by PI3K—RAC1—dilated cardiomyopathy	0.00176	0.00886	CbGpPWpGaD
Temsirolimus—MTOR—Wnt Signaling Pathway Netpath—GJA1—dilated cardiomyopathy	0.00176	0.00885	CbGpPWpGaD
Temsirolimus—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00174	0.00449	CcSEcCtD
Temsirolimus—Anorexia—Furosemide—dilated cardiomyopathy	0.00173	0.00447	CcSEcCtD
Temsirolimus—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00173	0.00446	CcSEcCtD
Temsirolimus—Chills—Lisinopril—dilated cardiomyopathy	0.00172	0.00444	CcSEcCtD
Temsirolimus—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00168	0.00434	CcSEcCtD
Temsirolimus—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00167	0.00431	CcSEcCtD
Temsirolimus—Erythema—Lisinopril—dilated cardiomyopathy	0.00167	0.00431	CcSEcCtD
Temsirolimus—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00164	0.00422	CcSEcCtD
Temsirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.00163	0.00821	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.00163	0.00817	CbGpPWpGaD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—RAC1—dilated cardiomyopathy	0.00162	0.00816	CbGpPWpGaD
Temsirolimus—Back pain—Lisinopril—dilated cardiomyopathy	0.00162	0.00417	CcSEcCtD
Temsirolimus—Somnolence—Furosemide—dilated cardiomyopathy	0.00162	0.00417	CcSEcCtD
Temsirolimus—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00158	0.00408	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00157	0.00405	CcSEcCtD
Temsirolimus—Fatigue—Furosemide—dilated cardiomyopathy	0.00157	0.00404	CcSEcCtD
Temsirolimus—Pain—Furosemide—dilated cardiomyopathy	0.00156	0.00401	CcSEcCtD
Temsirolimus—Constipation—Furosemide—dilated cardiomyopathy	0.00156	0.00401	CcSEcCtD
Temsirolimus—Anaemia—Lisinopril—dilated cardiomyopathy	0.00155	0.00398	CcSEcCtD
Temsirolimus—Angioedema—Lisinopril—dilated cardiomyopathy	0.00153	0.00394	CcSEcCtD
Temsirolimus—MTOR—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.0015	0.00756	CbGpPWpGaD
Temsirolimus—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0015	0.00386	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00149	0.00383	CcSEcCtD
Temsirolimus—Cough—Lisinopril—dilated cardiomyopathy	0.00146	0.00376	CcSEcCtD
Temsirolimus—MTOR—ErbB Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00144	0.00724	CbGpPWpGaD
Temsirolimus—MTOR—Interferon type I signaling pathways—RPS6KB1—dilated cardiomyopathy	0.00144	0.00724	CbGpPWpGaD
Temsirolimus—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00144	0.00371	CcSEcCtD
Temsirolimus—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00144	0.00371	CcSEcCtD
Temsirolimus—Myalgia—Lisinopril—dilated cardiomyopathy	0.00142	0.00367	CcSEcCtD
Temsirolimus—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00142	0.00367	CcSEcCtD
Temsirolimus—Chest pain—Lisinopril—dilated cardiomyopathy	0.00142	0.00367	CcSEcCtD
Temsirolimus—Anxiety—Lisinopril—dilated cardiomyopathy	0.00142	0.00366	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00141	0.00364	CcSEcCtD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—RAF1—dilated cardiomyopathy	0.00138	0.00695	CbGpPWpGaD
Temsirolimus—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00138	0.00694	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00137	0.00352	CcSEcCtD
Temsirolimus—Oedema—Lisinopril—dilated cardiomyopathy	0.00137	0.00352	CcSEcCtD
Temsirolimus—Infection—Lisinopril—dilated cardiomyopathy	0.00136	0.00349	CcSEcCtD
Temsirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.00135	0.00678	CbGpPWpGaD
Temsirolimus—MTOR—Wnt Signaling Pathway Netpath—RAC1—dilated cardiomyopathy	0.00134	0.00675	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00134	0.00345	CcSEcCtD
Temsirolimus—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00134	0.00344	CcSEcCtD
Temsirolimus—MTOR—IL4-mediated signaling events—IL10—dilated cardiomyopathy	0.00133	0.00667	CbGpPWpGaD
Temsirolimus—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00133	0.00342	CcSEcCtD
Temsirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.00132	0.00666	CbGpPWpGaD
Temsirolimus—Asthenia—Furosemide—dilated cardiomyopathy	0.00131	0.00336	CcSEcCtD
Temsirolimus—MTOR—Interferon type I signaling pathways—RAC1—dilated cardiomyopathy	0.0013	0.00655	CbGpPWpGaD
Temsirolimus—Anorexia—Lisinopril—dilated cardiomyopathy	0.0013	0.00335	CcSEcCtD
Temsirolimus—MTOR—IL4-mediated signaling events—RPS6KB1—dilated cardiomyopathy	0.00129	0.00649	CbGpPWpGaD
Temsirolimus—Pruritus—Furosemide—dilated cardiomyopathy	0.00129	0.00332	CcSEcCtD
Temsirolimus—MTOR—RANKL/RANK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00128	0.00645	CbGpPWpGaD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.00128	0.00645	CbGpPWpGaD
Temsirolimus—MTOR—IL12-mediated signaling events—FASLG—dilated cardiomyopathy	0.00127	0.00636	CbGpPWpGaD
Temsirolimus—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00124	0.00321	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00124	0.0032	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.00124	0.00623	CbGpPWpGaD
Temsirolimus—Insomnia—Lisinopril—dilated cardiomyopathy	0.00123	0.00318	CcSEcCtD
Temsirolimus—MTOR—mTOR signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00123	0.00617	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00123	0.00617	CbGpPWpGaD
Temsirolimus—MTOR—Class I PI3K signaling events mediated by Akt—RAF1—dilated cardiomyopathy	0.00122	0.00614	CbGpPWpGaD
Temsirolimus—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00122	0.00314	CcSEcCtD
Temsirolimus—Somnolence—Lisinopril—dilated cardiomyopathy	0.00121	0.00313	CcSEcCtD
Temsirolimus—Dizziness—Furosemide—dilated cardiomyopathy	0.0012	0.0031	CcSEcCtD
Temsirolimus—MTOR—Regulation of Telomerase—RPS6KB1—dilated cardiomyopathy	0.0012	0.00602	CbGpPWpGaD
Temsirolimus—MTOR—PI3K Cascade—RPS6KB1—dilated cardiomyopathy	0.0012	0.00602	CbGpPWpGaD
Temsirolimus—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00119	0.00306	CcSEcCtD
Temsirolimus—MTOR—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00118	0.00595	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00118	0.00304	CcSEcCtD
Temsirolimus—Fatigue—Lisinopril—dilated cardiomyopathy	0.00118	0.00303	CcSEcCtD
Temsirolimus—MTOR—CDC42 signaling events—RPS6KB1—dilated cardiomyopathy	0.00117	0.00589	CbGpPWpGaD
Temsirolimus—Constipation—Lisinopril—dilated cardiomyopathy	0.00117	0.00301	CcSEcCtD
Temsirolimus—Pain—Lisinopril—dilated cardiomyopathy	0.00117	0.00301	CcSEcCtD
Temsirolimus—Vomiting—Furosemide—dilated cardiomyopathy	0.00116	0.00298	CcSEcCtD
Temsirolimus—MTOR—Type II diabetes mellitus—TNF—dilated cardiomyopathy	0.00116	0.00581	CbGpPWpGaD
Temsirolimus—Rash—Furosemide—dilated cardiomyopathy	0.00115	0.00296	CcSEcCtD
Temsirolimus—Dermatitis—Furosemide—dilated cardiomyopathy	0.00115	0.00295	CcSEcCtD
Temsirolimus—MTOR—CXCR3-mediated signaling events—RAF1—dilated cardiomyopathy	0.00114	0.00575	CbGpPWpGaD
Temsirolimus—Headache—Furosemide—dilated cardiomyopathy	0.00114	0.00294	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.00113	0.00569	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00112	0.00288	CcSEcCtD
Temsirolimus—MTOR—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00111	0.00557	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—RAC1—dilated cardiomyopathy	0.00108	0.00544	CbGpPWpGaD
Temsirolimus—Nausea—Furosemide—dilated cardiomyopathy	0.00108	0.00278	CcSEcCtD
Temsirolimus—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00108	0.00278	CcSEcCtD
Temsirolimus—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00108	0.00278	CcSEcCtD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—RAF1—dilated cardiomyopathy	0.00108	0.00541	CbGpPWpGaD
Temsirolimus—MTOR—CDC42 signaling events—RAC1—dilated cardiomyopathy	0.00106	0.00532	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00101	0.00259	CcSEcCtD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—dilated cardiomyopathy	0.001	0.00504	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.001	0.00504	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.001	0.00503	CbGpPWpGaD
Temsirolimus—Asthenia—Lisinopril—dilated cardiomyopathy	0.000979	0.00252	CcSEcCtD
Temsirolimus—MTOR—IRS-related events—RPS6KB1—dilated cardiomyopathy	0.000975	0.0049	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—RPS6KB1—dilated cardiomyopathy	0.000966	0.00486	CbGpPWpGaD
Temsirolimus—Pruritus—Lisinopril—dilated cardiomyopathy	0.000966	0.00249	CcSEcCtD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAC1—dilated cardiomyopathy	0.00095	0.00478	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—dilated cardiomyopathy	0.000947	0.00476	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—RPS6KB1—dilated cardiomyopathy	0.000941	0.00473	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—RPS6KB1—dilated cardiomyopathy	0.000941	0.00473	CbGpPWpGaD
Temsirolimus—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000934	0.00241	CcSEcCtD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.000914	0.0046	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—RAC1—dilated cardiomyopathy	0.000914	0.0046	CbGpPWpGaD
Temsirolimus—Dizziness—Lisinopril—dilated cardiomyopathy	0.000903	0.00233	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000891	0.00448	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.000873	0.00439	CbGpPWpGaD
Temsirolimus—Vomiting—Lisinopril—dilated cardiomyopathy	0.000868	0.00224	CcSEcCtD
Temsirolimus—Rash—Lisinopril—dilated cardiomyopathy	0.000861	0.00222	CcSEcCtD
Temsirolimus—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00086	0.00222	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000859	0.00432	CbGpPWpGaD
Temsirolimus—Headache—Lisinopril—dilated cardiomyopathy	0.000855	0.0022	CcSEcCtD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.000851	0.00428	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000842	0.00424	CbGpPWpGaD
Temsirolimus—Nausea—Lisinopril—dilated cardiomyopathy	0.000811	0.00209	CcSEcCtD
Temsirolimus—MTOR—Signaling by Insulin receptor—RPS6KB1—dilated cardiomyopathy	0.000782	0.00393	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—RAC1—dilated cardiomyopathy	0.000765	0.00385	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—RAC1—dilated cardiomyopathy	0.000753	0.00379	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—RAF1—dilated cardiomyopathy	0.000744	0.00374	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—RAF1—dilated cardiomyopathy	0.000735	0.0037	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—RAF1—dilated cardiomyopathy	0.000735	0.0037	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—RAC1—dilated cardiomyopathy	0.000711	0.00358	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.000709	0.00357	CbGpPWpGaD
Temsirolimus—MTOR—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.000701	0.00353	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000682	0.00343	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000667	0.00335	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000664	0.00334	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000657	0.00331	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—dilated cardiomyopathy	0.00063	0.00317	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000606	0.00305	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.000604	0.00304	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.000604	0.00304	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—RAF1—dilated cardiomyopathy	0.0006	0.00302	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.000598	0.00301	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000594	0.00299	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.000592	0.00298	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—RAF1—dilated cardiomyopathy	0.000584	0.00294	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—RAF1—dilated cardiomyopathy	0.000579	0.00291	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000572	0.00288	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—RAF1—dilated cardiomyopathy	0.000564	0.00283	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—RAF1—dilated cardiomyopathy	0.000564	0.00283	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000563	0.00283	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000561	0.00282	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000559	0.00281	CbGpPWpGaD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.000555	0.00279	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000546	0.00275	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000541	0.00272	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000536	0.0027	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000535	0.00269	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000507	0.00255	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000507	0.00255	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000504	0.00253	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000504	0.00253	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.000499	0.00251	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000492	0.00248	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000471	0.00237	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.00047	0.00236	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000468	0.00235	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000437	0.0022	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000422	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000418	0.0021	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000408	0.00205	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000401	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000398	0.002	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000396	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000394	0.00198	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NPPA—dilated cardiomyopathy	0.000384	0.00193	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000383	0.00193	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000383	0.00193	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000377	0.0019	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PSEN2—dilated cardiomyopathy	0.000372	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000367	0.00185	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000365	0.00183	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000362	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.00036	0.00181	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000359	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000358	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000358	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000357	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000356	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000355	0.00178	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000348	0.00175	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000348	0.00175	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000343	0.00172	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000334	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000334	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000334	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000331	0.00166	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000328	0.00165	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000328	0.00165	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000327	0.00164	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.000308	0.00155	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000296	0.00149	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.000279	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000275	0.00138	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000272	0.00137	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000265	0.00133	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000265	0.00133	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000263	0.00132	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000261	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.00026	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000259	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000247	0.00124	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000246	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000246	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000246	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000245	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000243	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.00024	0.00121	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000237	0.00119	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000234	0.00118	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000231	0.00116	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000231	0.00116	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000229	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000229	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000229	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000227	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000227	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000225	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000224	0.00113	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000223	0.00112	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NPPA—dilated cardiomyopathy	0.000216	0.00109	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000216	0.00108	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000215	0.00108	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—dilated cardiomyopathy	0.000212	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PSEN2—dilated cardiomyopathy	0.000209	0.00105	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000208	0.00105	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000208	0.00105	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CD36—dilated cardiomyopathy	0.000208	0.00104	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000204	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000203	0.00102	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000202	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000199	0.001	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—RAC1—dilated cardiomyopathy	0.000196	0.000984	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000188	0.000945	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—RAC1—dilated cardiomyopathy	0.000187	0.000941	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000179	0.0009	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000179	0.0009	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000178	0.000894	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000169	0.000849	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000169	0.000848	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000168	0.000846	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000159	0.000797	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000156	0.000784	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000152	0.000765	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000147	0.000737	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000145	0.000729	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000143	0.000721	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ITGB1—dilated cardiomyopathy	0.000142	0.000713	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000135	0.00068	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000131	0.000659	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00013	0.000654	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00013	0.000654	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—RAF1—dilated cardiomyopathy	0.00013	0.000652	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000125	0.000629	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000125	0.000626	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—RAF1—dilated cardiomyopathy	0.000124	0.000624	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000121	0.000608	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD36—dilated cardiomyopathy	0.000121	0.000608	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000117	0.000589	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—RAC1—dilated cardiomyopathy	0.000114	0.000573	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.00011	0.000554	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RAC1—dilated cardiomyopathy	0.000105	0.000529	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000104	0.000521	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.0001	0.000503	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.49e-05	0.000477	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	9.37e-05	0.000471	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	9.27e-05	0.000466	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—dilated cardiomyopathy	8.9e-05	0.000447	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	8.83e-05	0.000444	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RAF1—dilated cardiomyopathy	8.69e-05	0.000437	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—dilated cardiomyopathy	8.54e-05	0.00043	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—dilated cardiomyopathy	8.51e-05	0.000428	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.15e-05	0.00041	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	7.58e-05	0.000381	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—RAF1—dilated cardiomyopathy	7.56e-05	0.00038	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	7.38e-05	0.000371	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAC1—dilated cardiomyopathy	7.37e-05	0.00037	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AGT—dilated cardiomyopathy	7.04e-05	0.000354	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RAF1—dilated cardiomyopathy	6.98e-05	0.000351	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	6.64e-05	0.000334	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—dilated cardiomyopathy	5.96e-05	0.0003	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	5.48e-05	0.000275	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.37e-05	0.00027	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	5.33e-05	0.000268	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—dilated cardiomyopathy	5.18e-05	0.000261	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAF1—dilated cardiomyopathy	4.89e-05	0.000246	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	4.8e-05	0.000242	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—dilated cardiomyopathy	4.78e-05	0.000241	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	4.13e-05	0.000208	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.03e-05	0.000202	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.89e-05	0.000196	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.79e-05	0.000191	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AGT—dilated cardiomyopathy	3.62e-05	0.000182	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	3.42e-05	0.000172	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—dilated cardiomyopathy	3.35e-05	0.000168	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.55e-05	0.000128	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.48e-05	0.000125	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.23e-05	0.000112	CbGpPWpGaD
